Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.

The blue-chip Dow Jones Industrial Average was on pace to exit correction territory on Thursday, after briefly flirting with bear-market territory during the lows of April sparked by President Trump's ...

U.K. trade front as a hopeful sign that more agreements can be reached, as President Trump starts making some headway on the trade fight he started months ago, said Peter Cardillo, chief market ...